Legal & General Group Plc Sells 269,910 Shares of Edwards Lifesciences Corporation $EW

Legal & General Group Plc decreased its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 6.0% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,223,892 shares of the medical research company’s stock after selling 269,910 shares during the quarter. Legal & General Group Plc owned approximately 0.72% of Edwards Lifesciences worth $330,351,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in EW. Nuveen LLC bought a new stake in shares of Edwards Lifesciences during the first quarter valued at approximately $330,881,000. Jennison Associates LLC increased its holdings in Edwards Lifesciences by 15.7% during the 2nd quarter. Jennison Associates LLC now owns 11,670,991 shares of the medical research company’s stock worth $912,788,000 after purchasing an additional 1,584,958 shares during the period. Primecap Management Co. CA raised its position in Edwards Lifesciences by 49.9% during the 2nd quarter. Primecap Management Co. CA now owns 3,446,891 shares of the medical research company’s stock valued at $269,581,000 after purchasing an additional 1,147,291 shares in the last quarter. Mirova US LLC raised its position in Edwards Lifesciences by 56.2% during the 2nd quarter. Mirova US LLC now owns 2,931,297 shares of the medical research company’s stock valued at $229,257,000 after purchasing an additional 1,054,301 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Edwards Lifesciences in the 2nd quarter worth $67,832,000. 79.46% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

EW has been the topic of several research reports. Mizuho raised their price target on Edwards Lifesciences from $90.00 to $100.00 and gave the company an “outperform” rating in a research note on Friday, October 31st. The Goldman Sachs Group set a $104.00 target price on shares of Edwards Lifesciences and gave the stock a “buy” rating in a report on Friday, October 31st. Wells Fargo & Company boosted their price target on shares of Edwards Lifesciences from $84.00 to $88.00 and gave the company an “overweight” rating in a report on Thursday, August 7th. Citigroup upped their price target on shares of Edwards Lifesciences from $95.00 to $96.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. Finally, Wall Street Zen lowered shares of Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a report on Monday, September 29th. Three analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Edwards Lifesciences has an average rating of “Moderate Buy” and an average target price of $91.39.

Insider Activity

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 13,000 shares of the firm’s stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $83.08, for a total value of $1,080,040.00. Following the completion of the sale, the chief financial officer owned 39,898 shares of the company’s stock, valued at approximately $3,314,725.84. This trade represents a 24.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 1,020 shares of the business’s stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $82.55, for a total value of $84,201.00. Following the sale, the vice president owned 22,002 shares in the company, valued at $1,816,265.10. The trade was a 4.43% decrease in their position. The disclosure for this sale is available in the SEC filing. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Price Performance

Shares of EW opened at $85.02 on Friday. The company has a 50 day moving average of $78.80 and a two-hundred day moving average of $78.07. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a twelve month low of $65.94 and a twelve month high of $87.21. The company has a market cap of $49.34 billion, a price-to-earnings ratio of 12.23, a price-to-earnings-growth ratio of 3.97 and a beta of 1.03.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.59 by $0.08. The firm had revenue of $1.55 billion during the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The business’s revenue for the quarter was up 14.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. As a group, analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.